New hope for advanced bladder cancer: maintenance therapy after combo treatment
NCT ID NCT07221942
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a maintenance drug (pembrolizumab) can help control advanced bladder cancer after an initial 18-week combination treatment. About 97 people who have not had prior therapy for metastatic disease will participate. The goal is to see if this approach improves how long the cancer stays under control and overall survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fox Chase Cancer Center - Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19111-2497, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted drug hunts down cancer cells in advanced bladder cancer trial
- New drug option for Hard-to-Treat cancers with FGFR3 mutations
- New bladder cancer drug aims to fight tumors without harming nerves
- New hope for advanced bladder cancer? bevacizumab combo tested
- New cocktail of drugs takes on Hard-to-Treat bladder cancer
- New imaging tracer could spot hidden cancers